Public health company the US Food and Drug Administration stated on Friday that it has authorised the marketing of the first drug TPOXX (tecovirimat) for treatment of smallpox.
This US FDA approval of TPOXX was awarded to SIGA Technologies Inc under the former's fast track, priority review and orphan drug designations. The drug was developed in conjunction with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
Although the World Health Organisation declared in 1980 that smallpox, a contagious and sometimes fatal infectious disease, was eradicated, there have been longstanding concerns that smallpox could be used as a bioweapon. Complications of smallpox could include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.
TPOXX was approved under the US FDA's Animal Rule, which allows efficacy findings from adequate and well-controlled animal studies to support an US FDA approval when it is not feasible or ethical to conduct efficacy trials in humans. The drug's effectiveness against smallpox was based on measuring survival at the end of the studies. More animals treated with TPOXX lived compared to the animals treated with placebo.
Additionally, the safety of the company's TPOXX was evaluated in 359 healthy human volunteers without a smallpox infection. The most frequently reported side effects were headache, nausea and abdominal pain.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007